Sharda Cropchem: Business Overview & Financial Analysis
Sharda Cropchem is an agrochemicals and non-agrochemicals marketing and distribution enterprise headquartered in Mumbai, Maharashtra. Promoted by Ramprakash V. Bubna and family, the company operates an asset-light, IP-driven business model centered on identifying generic active ingredients, preparing technical dossiers, obtaining registrations, and marketing crop protection chemical products alongside industrial goods across 80+ countries globally.
Business Segment Revenue Mix of Sharda Cropchem (Q1 FY2027)
Sharda Cropchem categorises its operational turnover across core crop protection chemicals and non-agrochemical industrial product divisions.
- Agrochemicals Division Share – 85.2% of Total Operating Revenue (Rs 915.00 crore)
- Non-Agrochemicals Division Share – 14.8% of Total Operating Revenue (Rs 159.00 crore)
- Total Consolidated Revenue from Operations (Q1 FY2027) – Rs 1,074.00 crore (+9.0% YoY)
Agrochemicals serve as the primary top-line engine, processing sales across herbicides, insecticides, and fungicides. Non-agrochemical sales provide business diversification through industrial conveyor belts, specialty chemicals, and dyes.
Agrochemical Product Portfolio Breakdown of Sharda Cropchem (Q1 FY2027)
Sharda Cropchem structures its core crop protection product dispatches across weed control herbicides, pest control insecticides, and fungal treatment products.
- Herbicides Product Share – 50.0% of Agrochemical Revenue (Rs 457.00 crore)
- Insecticides Product Share – 25.5% of Agrochemical Revenue (Rs 233.00 crore)
- Fungicides Product Share – 24.5% of Agrochemical Revenue (Rs 225.00 crore)
Herbicides account for half of total crop protection turnover, benefiting from strong seasonal demand across European and North American farming belts. Insecticides and fungicides expand product coverage across diverse agricultural crop cycles.
Geographic Revenue Breakdown of Sharda Cropchem (FY2026)
Sharda Cropchem generates over nine-tenths of its agrochemical turnover from international export markets across Europe, North America, and Latin America.
- Europe Region Sales Share – 63.0% of Agrochemical Revenue (Rs 2,981.00 crore)
- NAFTA Region (USA, Canada & Mexico) Share – 27.0% of Agrochemical Revenue (Rs 1,266.00 crore)
- Latin America (LATAM) Region Share – 5.0% of Agrochemical Revenue (Rs 254.00 crore)
- Rest of the World (RoW) Region Share – 5.0% of Agrochemical Revenue (Rs 216.00 crore)
Europe represents the largest revenue contributor, yielding higher gross margins due to stringent entry barriers for chemical registrations. NAFTA and LATAM provide multi-season geographic diversification across Northern and Southern Hemisphere farming cycles.
Intellectual Property & Product Registration Scale of Sharda Cropchem (Q1 FY2027)
Sharda Cropchem invests in building a proprietary intellectual property portfolio of global crop protection registrations and regulatory filings.
- Total Global Product Registrations Base – 3,016 registered formulation dossiers
- Active Pending Registration Applications – 1,027 pending applications globally
- Average Cost Per Product Registration – ~$4.0 million per registration package
- Average Approval Timeline Corridor – 2 to 10 years depending on target jurisdiction
- Annual Registration Capex Outlay Guidance – Rs 400–450 crore per annum
A portfolio of 3,016 global product registrations serves as a high competitive barrier to entry against generic peers. Continuous investment in filing 1,027 pending applications secures long-term market access across regulated international jurisdictions.
Asset-Light Operating Model & Distribution Reach of Sharda Cropchem (FY2026)
Sharda Cropchem operates an asset-light corporate structure that eliminates manufacturing plant ownership while focusing on IP registration and product marketing.
- Manufacturing Facilities Owned – 0 owned plants (100% outsourced manufacturing)
- Third-Party Global Distributors Base – 525+ authorised distribution partners
- Dedicated In-House Sales & Marketing Force – 500+ commercial personnel
- Global Geographic Presence Reach – Active sales across 80+ countries
Outsourcing 100% of physical manufacturing avoids heavy plant capital expenditure and fixed overhead expenses. Channel relationships with 525+ third-party distributors and a 500-strong sales team drive global product distribution.
Latest Quarterly Financial Performance of Sharda Cropchem (Q1 FY2027)
Sharda Cropchem recorded top-line revenue expansion and operating profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 1,074.00 crore (+9.0% YoY)
- Consolidated Operating EBITDA – Rs 178.00 crore (+25.0% YoY)
- Operating EBITDA Margin – 16.60% (+220 bps YoY)
- Gross Profit Margin Realisation – 36.70% (+120 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 88.02 crore (-38.0% YoY)
First-quarter operating revenue rose 9.0% year-on-year to Rs 1,074.00 crore, supported by an 8.1% growth in agrochemical dispatches. Operating EBITDA expanded 25.0% to Rs 178.00 crore, while Net Profit After Tax was impacted by lower foreign exchange gains compared to the prior year base.
Consolidated Annual Financial Performance of Sharda Cropchem (FY2026)
Sharda Cropchem achieved record full-year turnover expansion and bottom-line earnings growth for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 5,267.60 crore (+21.9% YoY)
- Full Year Consolidated Operating EBITDA – Rs 1,039.50 crore (+69.5% YoY)
- Full Year Operating EBITDA Margin – 19.73% (+550 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 681.00 crore (+123.7% YoY)
- Full Year Final Dividend Declared – Rs 9.00 per equity share
Full-year operating turnover crossed Rs 5,260 crore in FY2026, as consolidated Net Profit After Tax expanded 123.7% to Rs 681.00 crore. Financial performance was driven by a 13.4% volume expansion, gross margin expansion to 37.3%, and favorable foreign exchange realisations.
Balance Sheet Structure & Financial Health Ratios of Sharda Cropchem (Q1 FY2027)
Sharda Cropchem operates a debt-free financial model backed by strong liquid cash reserves and working capital cycle compression.
- Financial Debt to Equity Ratio – Zero Debt / Net Cash Surplus (0.00x)
- Total Cash, Bank Balances & Surplus Investments – Rs 767.00 crore
- Total Consolidated Net Worth Base – Rs 3,245.00 crore
- Working Capital Cycle – 98 days (compressed from 118 days in FY2025)
The enterprise closed Q1 FY2027 with a zero-debt balance sheet and Rs 767.00 crore in liquid surplus reserves. Net working capital compressed to 98 days, reflecting inventory normalization across international distribution channels.
Capital Allocation & Registration Outlay Roadmap of Sharda Cropchem (FY2027–FY2028)
Sharda Cropchem executes capital allocation outlays dedicated to acquiring global product registrations and expanding direct sales channels.
- Planned Annual Registration Capex Outlay – Rs 400–450 crore per annum over FY2027–FY2028
- Target Regulatory Jurisdictions – Europe, NAFTA, and Latin American crop protection markets
- Forward Integration Strategy – Expanding in-house commercial sales teams in core European markets
- Funding Method – 100% funded through internal operational cash accruals and cash reserves
Annual capital expenditure is budgeted at Rs 400–450 crore over FY2027–FY2028 to secure new product formulation registrations. Internal operational cash flows fully fund all planned registration investments without external borrowing.
Strategic Outlook & Management Commentary of Sharda Cropchem (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on top-line volume growth, product registration expansion, and debt-free balance sheet preservation.
- Management targets achieving a 10%–15% annual top-line revenue CAGR over full financial year FY2027.
- Consolidated operating EBITDA margins are guided to sustain within the 15.0%–16.0% corridor.
- Global product registration pipeline will be expanded by adding 100+ net new registrations annually.
- Direct sales presence in core European and North American markets will be strengthened through forward integration.
- Capital allocation strategy will prioritize maintaining a debt-free balance sheet while reinvesting cash flows into high-margin dossiers.
Management anticipates steady demand recovery across European and North American crop protection markets to support dispatch volumes. Operational focus centers on obtaining pending product approvals, expanding direct distributor coverage, and maintaining balance sheet strength.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Sharda Cropchem Q1 FY2027 Consolidated Financial Disclosures & Press Release (July 29 / August 4, 2026)
- Sharda Cropchem Investor Presentation & Stock Exchange Outcomes
- Sharda Cropchem Corporate Filings & Earnings Call Transcripts
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Sharda Cropchem
- Ticker Finology Sharda Cropchem Page
Disclaimer
The information presented above on Sharda Cropchem has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Sharda Cropchem page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.